We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$911M
AUM Growth
-$47.6M
Cap. Flow
-$18.7M
Cap. Flow %
-2.05%
Top 10 Hldgs %
30.91%
Holding
97
New
4
Increased
33
Reduced
45
Closed
9

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$18.3M
2
MCK icon
McKesson
MCK
+$8.31M
3
COO icon
Cooper Companies
COO
+$7.22M
4
ABT icon
Abbott
ABT
+$7.18M
5
CI icon
Cigna
CI
+$6.56M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$32.2M
2
JNJ icon
Johnson & Johnson
JNJ
+$17.7M
3
MDT icon
Medtronic
MDT
+$9.37M
4
PFE icon
Pfizer
PFE
+$6.91M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$6.48M

Sector Composition

Rank Sector Weight
1 Healthcare 95.19%
2 Industrials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
51
DELISTED
Exact Sciences
EXAS
$5.96M 0.65%
90,000
-20,000
-18% -$1.29M
ITCI
52
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.89M 0.65%
105,000
-20,000
-16% -$967K
EW icon
53
Edwards Lifesciences
EW
$53.9B
$5.71M 0.63%
70,000
-74,000
-51% -$5.82M
HRMY icon
54
Harmony Biosciences
HRMY
$2.29B
$5.56M 0.61%
170,000
-70,000
-29% -$3.19M
WST icon
55
West Pharmaceutical
WST
$24.9B
$5.11M 0.56%
15,000
-10,000
-40% -$2.92M
IMGN
56
DELISTED
Immunogen Inc
IMGN
$4.64M 0.51%
1,250,000
-250,000
-17% -$1.07M
GKOS icon
57
Glaukos
GKOS
$10.8B
$4.53M 0.5%
92,000
+7,000
+8% +$340K
RCM
58
DELISTED
R1 RCM Inc. Common Stock
RCM
$4.49M 0.49%
300,000
-78,000
-21% -$1.07M
IOVA icon
59
Iovance Biotherapeutics
IOVA
$2.89B
$4.22M 0.46%
686,170
-178,208
-21% -$1.23M
IQV icon
60
IQVIA
IQV
$40.3B
$4.09M 0.45%
21,000
+1,000
+5% +$214K
TECH icon
61
Bio-Techne
TECH
$11.2B
$3.98M 0.44%
55,000
-35,000
-39% -$2.7M
HCAT icon
62
Health Catalyst
HCAT
$137M
$3.87M 0.42%
340,000
+160,000
+89% +$2.04M
OLK
63
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$3.8M 0.42%
174,300
-20,090
-10% -$438K
ALKS icon
64
Alkermes
ALKS
$8.29B
$3.76M 0.41%
135,000
-15,000
-10% -$409K
PHR icon
65
Phreesia
PHR
$773M
$3.7M 0.41%
120,000
-30,000
-20% -$1.06M
VRAY
66
DELISTED
ViewRay, Inc.
VRAY
$3.32M 0.36%
1,000,000
– –
VKTX icon
67
Viking Therapeutics
VKTX
$3.95B
$3.12M 0.34%
+180,000
New +$1.86M
RLAY icon
68
Relay Therapeutics
RLAY
$4.38B
$3.02M 0.33%
190,000
-10,000
-5% -$179K
MGTX icon
69
MeiraGTx Holdings
MGTX
$1.2B
$2.8M 0.31%
538,986
-16,044
-3% -$111K
NVCR icon
70
NovoCure
NVCR
$2.03B
$2.62M 0.29%
45,000
+10,000
+29% +$799K
NUVL
71
DELISTED
Nuvalent
NUVL
$2.54M 0.28%
100,000
+20,000
+25% +$591K
ISRG icon
72
Intuitive Surgical
ISRG
$141B
$2.51M 0.28%
10,000
+5,000
+100% +$1.23M
BBIO icon
73
BridgeBio Pharma
BBIO
$16.6B
$2.32M 0.25%
+135,000
New +$1.57M
ARVN icon
74
Arvinas
ARVN
$584M
$2.28M 0.25%
85,000
– –
AGL icon
75
Agilon Health
AGL
$1.5B
$2.1M 0.23%
3,600
-6,600
-65% -$3.7M
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2023 Portfolio in Review

As of Q1 2023, Rhenman & Partners Asset Management held 97 positions worth $911M, down 5% from $958M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management's Q1 2023 filing shows 4 new, 33 increased, 45 reduced and 9 closed positions. Its largest new stake was Viking Therapeutics: 180,000 shares worth $3.12M. The largest sale was Eli Lilly, an estimated $32.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q1 2023 buy was Viking Therapeutics: 180,000 shares worth $3.12M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q1 2023, an estimated $18.3M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2023 reduction was Medtronic, cutting an estimated $9.37M.
  • Rhenman & Partners Asset Management fully exited Eli Lilly in Q1 2023, selling an estimated $32.2M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $911M portfolio in Q1 2023.
  • Rhenman & Partners Asset Management opened 4 new positions and closed 9 in Q1 2023.
  • Rhenman & Partners Asset Management's portfolio value fell 5% quarter-over-quarter to $911M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2023, filed 12 May 2023.